INTS
|Intensity Therapeutics, Inc. Common stock
NASDAQ
USD 0.32
+0.03|+11.58%
Current Price
USD 0.32
Change
+USD 0.03 (11.58%)
P/E Ratio
Dividend Yield
Market Cap
8.52M
Volume
4.22M
Open
USD 0.29
Previous Close
USD 0.29
52-Week High
USD 5.10
52-Week Low
USD 0.29
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Lewis H. Bender M.A., M.B.A., M.S.
Employees:5
Headquarters:Shelton, USA
Website:www.intensitytherapeutics.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions